Evaluating the efficacy of basiliximab versus no induction in low-immunological-risk kidney transplant recipients: a propensity score matched analysis
In low-immunological-risk KTRs, no induction therapy achieves comparable AR prevention and renal function outcomes to BSX while reducing infection and hematological complications. These findings challenge the necessity of universal induction therapy in this population and support a personalized approach to immunosuppression protocols.
Authors
- Zhiying Lei
- Rong Ma (ORCID: https://orcid.org/0009-0003-6001-9221)
- Jun Yin (ORCID: https://orcid.org/0000-0002-9826-3583)
- Xuyong Sun (ORCID: https://orcid.org/0000-0002-2098-2510)
- D Y Zhang
- Haibin Li (ORCID: https://orcid.org/0000-0002-6932-982X)
- Jiqiu Wen (ORCID: https://orcid.org/0000-0003-0021-7712)
- Ning Wen (ORCID: https://orcid.org/0000-0001-9059-2406)
- Jihua Wu
- Shijian Li (ORCID: https://orcid.org/0000-0001-5846-3065)
- Jianhui Dong
Institutions
- Guangxi Medical University (CN)
Publication Details
- Journal
- Renal Failure
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1080/0886022x.2025.2460729
- Citations
- 2
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.97
Funders
- Guangxi Key Research and Development Program